Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19.

ABSTRACT: Drug repurposing provides a rapid approach to meet the urgent need for therapeutics to address COVID-19. To identify therapeutic targets relevant to COVID-19, we conducted Mendelian randomization analyses, deriving genetic instruments based on transcriptomic and proteomic data for 1,263 actionable proteins that are targeted by approved drugs or in clinical phase of drug development. Using summary statistics from the Host Genetics Initiative and the Million Veteran Program, we studied 7,554 patients hospitalized with COVID-19 and >1 million controls. We found significant Mendelian randomization results for three proteins (ACE2, P = 1.6 × 10^-6; IFNAR2, P = 9.8 × 10^-11 and IL-10RB, P = 2.3 × 10^-14) using cis-expression quantitative trait loci genetic instrumen

SUBMITTER: Gaziano L 

PROVIDER: S-EPMC7612986 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature